Literature DB >> 2372985

Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

M Grazia Cifone1, R Giacomelli, G Famularo, R Paolini, C Danese, T Napolitano, A Procopio, A M Perego, A Santoni, G Tonietti.   

Abstract

Enhanced natural killer (NK) activity and normal lymphocyte antibody-dependent cellular cytotoxicity (ADCC) were observed in 16 patients with a diagnosis of progressive systemic sclerosis (PSS). Higher NK activity levels were observed against NK-sensitive K562 target cells, while the NK-resistant P815, Daudi and Raji cell lines were not lysed. Cytofluorimetric studies and morphological analysis of peripheral blood lymphocytes (PBL) showed an increased number of CD16 positive cells and large granular lymphocytes (LGL), indicating that the enhancement observed was probably attributable to an increase in the number of circulating NK cells.

Entities:  

Mesh：

Year:  1990        PMID： 2372985      PMCID： PMC1535192          DOI： 10.1111/j.1365-2249.1990.tb03293.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  43 in total

1.  Correlation between natural and antibody-dependent cell-mediated cytotoxicity against tumor targets in the mouse. I. Distribution of the reactivity.

Authors:  A Santoni; R B Herberman; H T Holden
Journal:  J Natl Cancer Inst       Date:  1979-01       Impact factor: 13.506

2.  Natural killing and antibody-dependent cellular cytotoxicity are mediated by different mechanisms and by different cells.

Authors:  H S Koren; M S Williams
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

3.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins.

Authors:  G Trinchieri; D Santoli; H Koprowski
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Polyclonal B lymphocyte activation in progressive systemic sclerosis.

Authors:  G Famularo; R Giacomelli; E Alesse; M G Cifone; S Morrone; M Boirivant; C Danese; M A Perego; A Santoni; G Tonietti
Journal:  J Clin Lab Immunol       Date:  1989-06

6.  Subpopulations of human T lymphocytes. IX. Imbalance of T cell subpopulations in patients with progressive systemic sclerosis.

Authors:  S Gupta; A N Malaviya; P Rajagopalan; R A Good
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma).

Authors:  N F Rothfield; G P Rodnan
Journal:  Arthritis Rheum       Date:  1968-10

9.  Natural killing in immunodeficient patients.

Authors:  H S Koren; D B Amos; R H Buckley
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

10.  Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction.

Authors:  R M Welsh
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307
View more
  8 in total

1.  Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization.

Authors:  R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients.

Authors:  R Giacomelli; A Passacantando; G Frieri; I Parzanese; S D'Alò; P Vernia; M T Pimpo; C Petrucci; R Caprilli; M G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

4.  Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.

Authors:  Anne-Sophie Dugast; Andrew Tonelli; Christoph T Berger; Margaret E Ackerman; Gaia Sciaranghella; Qingquan Liu; Magdalena Sips; Ildiko Toth; Alicja Piechocka-Trocha; Musie Ghebremichael; Galit Alter
Journal:  Virology       Date:  2011-05-12       Impact factor: 3.616

5.  Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

Authors:  G Famularo; A Procopio; R Giacomelli; C Danese; S Sacchetti; M A Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

6.  CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.

Authors:  R Gorla; P Airò; A Malagoli; G Carella; E Prati; D Brugnoni; F Franceschini; R Cattaneo
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

7.  Natural killer cells and gamma delta T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies.

Authors:  R F Holcombe; B A Baethge; R E Wolf; K W Betzing; R M Stewart
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

8.  Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.

Authors:  Paola Di Benedetto; Giuliana Guggino; Giovanna Manzi; Piero Ruscitti; Onorina Berardicurti; Noemi Panzera; Nicolò Grazia; Roberto Badagliacca; Valeria Riccieri; Carmine Dario Vizza; Ganna Radchenko; Vasiliki Liakouli; Francesco Ciccia; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2020-06-01       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.